Inhibikase Therapeutics | 8-K: Current report
Apr 30 08:20 ET
Inhibikase Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
Apr 29 16:41 ET
Inhibikase Therapeutics | DEFA14A: Others
Apr 26 16:38 ET
Inhibikase Therapeutics | ARS: Annual Report to Security Holders
Apr 26 16:27 ET
Inhibikase Therapeutics | DEF 14A: Definitive information statements
Apr 26 16:21 ET
Inhibikase Therapeutics | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
Apr 25 16:31 ET
Inhibikase Therapeutics | S-1: General form for registration of securities under the Securities Act of 1933
Apr 19 17:15 ET
Inhibikase Therapeutics | 8-K: Current report
Apr 19 06:11 ET
Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Apr 15 16:14 ET
Inhibikase Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Werner Milton H.
Apr 3 16:51 ET
Inhibikase Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Lees-Rolfe Garth
Apr 2 17:17 ET
Inhibikase Therapeutics | 8-K/A: Current report (Amendment)
Apr 2 17:17 ET
Inhibikase Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Lees-Rolfe Garth
Apr 2 17:17 ET
Inhibikase Therapeutics | 10-K: Annual report
Mar 27 16:12 ET
Inhibikase Therapeutics | 8-K: Current report
Feb 7 08:01 ET
Inhibikase Therapeutics | 424B5: Prospectus
Feb 1 16:54 ET
Inhibikase Therapeutics | 8-K: Current report
Feb 1 16:14 ET
Inhibikase Therapeutics | 8-K: Current report
Jan 16 00:00 ET
Inhibikase Therapeutics: Q3 2023 Earnings Report
Nov 14, 2023 16:15 ET
Inhibikase Therapeutics | 10-K/A: Annual report (Amendment)
Oct 16, 2023 17:24 ET
No Data
No Data